The emerging pipeline of CAR-T in NHL includes late-stage, mid-stage, and early-stage drugs in different lines of therapies and different indications, mainly including B- cell Lymphoma such as DLBCL, FL, MCL, MZL, CLL/SLL, and others, with one of them being developed...
In January, the FDA published, “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products: Guidance for Industry.” To find out how this guidance impacts the CAR-T industry, GEN talked with Klara Sochorová, PhD, senior quality compliance...
Brazil’s Ministry of Health is working with a US nonprofit to locally manufacture CAR-T therapies and potentially other cell and gene therapies at a much lower cost. The goal is to provide cell therapy free of charge to patients while charging Brazil’s health system...
The “CAR-T Funding Report – Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024” report has been added to ResearchAndMarkets.com’s offering. For the nascent CAR-T industry, it is a phenomenal achievement to...
It isn’t often that a single company has an advisory committee meeting for one product and an FDA decision for another in the same week. Even more unusual is when the two drugs are of the same therapeutic class. That’s what’s happening this week for Bristol Myers...
